Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anastrozole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 19/20 | 1.00 |
| ▸ | UGT1A4 | P22310 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anastrozole SCHEMBL177942 | 1.00 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL27927481 | 1.00 | CYP19A1 (1.00) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL28771766 | 0.99 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL5917785 | 0.99 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL3172308 | 0.99 | CYP19A1 (0.97) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL10324455 | 0.96 | CYP19A1 (0.92) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL13323739 | 0.95 | CYP19A1 (0.90) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL8059026 | 0.93 | CYP19A1 (0.87) | CYP19A1UGT1A4PDE4DESR1STS | |
| Anastrozole SCHEMBL354747 | 0.92 | CYP19A1 (0.85) | CYP19A1UGT1A4PDE4DESR1STS | |
| SCHEMBL12908863 | 0.92 | CYP19A1 (0.85) | CYP19A1UGT1A4PDE4DESR1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 97442 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| EP-4745155-A1 | POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT | National Institute for Materials Science (JP) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2026100645-A1 | METHODS FOR TREATING VASOMOTOR SYMPTOMS IN BREAST CANCER PATIENTS WITH FEZOLINETANT | ASTELLAS PHARMA INC. (JP) | 2026-05-15 | — | — | WO | claimed |
| WO-1997037649-A1 | METHOD OF REDUCING NEPHROTOXICITY | MERCK & CO., INC. (US) | 1997-10-16 | — | — | WO | claimed |
| WO-1997032588-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE AND AROMATASE INHIBITORS AND USE OF THIS COMBINATION TO PRODUCE A MEDICAMENT FOR TREATING RELATIVE AND ABSOLUTE ANDROGEN DEFICIENCY IN MEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-09-12 | — | — | WO | claimed |
| EP-0782450-A1 | USE OF AROMATASE INHIBITORS IN THE PREPARATION OF A DRUG FOR TREATING A RELATIVE ANDROGEN DEFICIENCY IN MEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009057-A1 | USE OF AROMATASE INHIBITORS IN THE PREPARATION OF A DRUG FOR TREATING A RELATIVE ANDROGEN DEFICIENCY IN MEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-03-28 | — | — | WO | claimed |
| EP-0296749-B1 | (Substituted aralkyl) heterocyclic compounds | ZENECA LTD (GB) | 1994-10-26 | — | — | EP | claimed |
| EP-0516278-A1 | Use of anti-mullerian hormone for reversal of female sexual phenotype in poultry | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | claimed |
| EP-0514015-A1 | Control of sex differentiation in fish | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | claimed |
| US-5162337-A | Administering Steroid Biosynthesis Inhibitors | MERCK & CO., INC. (US) | 1992-11-10 | — | — | US | claimed |
| EP-0433084-A2 | Use of aromatese inhibitors for the reversal of female sexual phenotype in poultry | MERCK & CO. INC. (US) | 1991-06-19 | — | — | EP | claimed |
| US-4935437-A | (Substituted aralkyl) heterocyclic compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-19 | — | — | US | claimed |